See more : Amundi S.A. (AMDUF) Income Statement Analysis – Financial Results
Complete financial analysis of Genfit S.A. (GNFT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genfit S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sinopharm Tech Holdings Limited (8156.HK) Income Statement Analysis – Financial Results
- Neurocrine Biosciences, Inc. (NBIX) Income Statement Analysis – Financial Results
- Sarissa Capital Acquisition Corp. (SRSA) Income Statement Analysis – Financial Results
- JZ Capital 2021 6% CULS (JZCC.L) Income Statement Analysis – Financial Results
- IT Link SA (ALITL.PA) Income Statement Analysis – Financial Results
Genfit S.A. (GNFT)
About Genfit S.A.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.57M | 20.20M | 80.07M | 765.00K | 30.84M | 69.00K | 118.00K | 284.00K | 527.00K | 1.61M | 1.90M | 1.67M | 2.36M | 3.76M | 5.81M | 8.76M | 9.48M | 10.05M | 12.77M |
| Cost of Revenue | 341.00K | 248.00K | 161.00K | 202.00K | 177.00K | 1.85M | 2.23M | 1.99M | 1.93M | 1.40M | 1.29M | 1.20M | 1.41M | 1.37M | 1.61M | 1.74M | 2.01M | 1.69M | 1.32M |
| Gross Profit | 28.22M | 19.95M | 79.91M | 563.00K | 30.66M | -1.79M | -2.11M | -1.70M | -1.40M | 210.10K | 606.40K | 477.20K | 949.30K | 2.39M | 4.21M | 7.02M | 7.47M | 8.37M | 11.46M |
| Gross Profit Ratio | 98.81% | 98.77% | 99.80% | 73.59% | 99.43% | -2,586.96% | -1,788.98% | -598.94% | -266.41% | 13.01% | 31.93% | 28.54% | 40.21% | 63.57% | 72.37% | 80.10% | 78.84% | 83.23% | 89.68% |
| Research & Development | 46.71M | 35.82M | 35.17M | 59.10M | 66.17M | 47.66M | 35.10M | 19.19M | 5.39M | 9.02M | 5.16M | 4.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.04M | 16.41M | 16.15M | 14.27M | 17.27M | 13.63M | 13.41M | 11.66M | 9.13M | 9.37M | 7.38M | 6.45M | 6.02M | 6.91M | 0.00 | 0.00 | 6.20M | 4.81M | 4.71M |
| Selling & Marketing | 0.00 | 992.00K | 1.54M | 11.22M | 13.71M | 717.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.04M | 17.40M | 17.69M | 25.49M | 30.97M | 13.63M | 13.41M | 11.66M | 9.13M | 9.37M | 7.38M | 6.45M | 6.02M | 6.91M | 0.00 | 0.00 | 6.20M | 4.81M | 4.71M |
| Other Expenses | 53.00K | -5.72M | -4.75M | -6.23M | -8.47M | 6.41M | 6.08M | 1.61M | 1.75M | 100.00 | -1.51M | -100.00 | 2.68M | 3.14M | 10.69M | 12.20M | 7.27M | 4.11M | 5.07M |
| Operating Expenses | 54.80M | 47.50M | 48.11M | 78.35M | 88.67M | 67.70M | 54.58M | 32.46M | 16.27M | 17.48M | 11.02M | 8.19M | 8.70M | 10.04M | 10.69M | 12.20M | 13.47M | 8.92M | 9.78M |
| Cost & Expenses | 55.15M | 47.50M | 48.11M | 78.35M | 88.67M | 69.55M | 56.81M | 34.44M | 18.20M | 18.88M | 12.32M | 9.39M | 10.11M | 11.41M | 12.29M | 13.94M | 15.47M | 10.61M | 11.10M |
| Interest Income | 1.71M | 8.21M | 44.78M | 6.54M | 5.22M | 202.00K | 389.00K | 316.00K | 437.00K | 329.00K | 169.20K | 201.40K | 322.80K | 205.70K | 300.90K | 596.00K | 768.90K | 399.70K | 53.40K |
| Interest Expense | 4.62M | 4.76M | 7.12M | 25.30M | 13.11M | 10.98M | 1.39M | 110.00K | 0.00 | 93.70K | 103.10K | 238.40K | 372.80K | 391.40K | 449.10K | 205.20K | 390.80K | 308.80K | 332.90K |
| Depreciation & Amortization | 1.65M | 1.83M | 2.74M | 4.75M | 5.25M | 1.44M | 1.53M | 799.00K | 327.00K | 292.10K | 465.50K | 556.30K | 788.80K | 919.60K | 1.06M | 1.00M | 943.90K | 537.70K | 874.40K |
| EBITDA | -22.24M | -23.60M | 34.91M | -91.14M | -51.02M | -68.08M | -55.76M | -33.53M | -17.35M | -16.98M | -9.95M | -6.77M | -6.64M | -6.53M | -5.09M | -3.41M | -4.07M | 930.30K | 2.60M |
| EBITDA Ratio | -77.84% | -85.45% | 99.26% | -8,821.70% | -153.07% | -97,182.61% | -46,264.41% | -11,550.70% | -3,146.30% | -1,029.08% | -509.17% | -405.08% | -281.18% | -173.79% | -88.67% | -40.07% | -43.19% | 1.16% | 20.38% |
| Operating Income | -26.58M | -27.55M | 76.74M | -77.79M | -57.83M | -69.48M | -56.70M | -34.16M | -17.68M | -17.26M | -10.51M | -7.72M | -7.75M | -7.66M | -6.47M | -5.17M | -5.99M | -553.30K | 1.68M |
| Operating Income Ratio | -93.05% | -136.41% | 95.84% | -10,168.76% | -187.53% | -100,701.45% | -48,046.61% | -12,027.46% | -3,354.08% | -1,069.04% | -553.56% | -461.39% | -328.32% | -203.82% | -111.40% | -59.06% | -63.21% | -5.50% | 13.12% |
| Total Other Income/Expenses | -1.93M | 3.45M | -7.26M | -18.75M | -7.89M | -10.39M | -2.45M | 526.00K | 541.00K | 234.00K | 179.60K | -13.60K | -50.00K | -185.70K | -177.50K | 559.20K | 611.00K | 223.60K | 33.40K |
| Income Before Tax | -28.51M | -23.84M | 69.47M | -101.65M | -65.72M | -79.88M | -58.22M | -33.63M | -17.14M | -17.03M | -10.33M | -7.73M | -7.80M | -7.84M | -6.65M | -4.71M | -5.38M | -329.70K | 1.71M |
| Income Before Tax Ratio | -99.82% | -118.03% | 86.77% | -13,287.45% | -213.11% | -115,760.87% | -49,338.14% | -11,841.55% | -3,251.42% | -1,054.57% | -544.10% | -462.21% | -330.44% | -208.76% | -114.46% | -53.79% | -56.76% | -3.28% | 13.38% |
| Income Tax Expense | 380.00K | -116.00K | 2.22M | -428.00K | -576.00K | -354.00K | 384.00K | 35.00K | 227.00K | 400.00 | 2.32M | -2.32M | 1.88M | 1.54M | 721.50K | -751.40K | -2.58M | -665.40K | 74.40K |
| Net Income | -28.89M | -23.72M | 67.26M | -101.22M | -65.15M | -79.52M | -58.60M | -33.67M | -17.14M | -17.03M | -12.65M | -5.41M | -9.68M | -9.38M | -7.37M | -3.96M | -2.80M | 327.70K | 1.77M |
| Net Income Ratio | -101.15% | -117.45% | 84.00% | -13,231.50% | -211.24% | -115,247.83% | -49,664.41% | -11,854.58% | -3,251.42% | -1,054.60% | -666.15% | -323.60% | -410.09% | -249.65% | -126.87% | -45.21% | -29.55% | 3.26% | 13.88% |
| EPS | -0.58 | -0.48 | 1.50 | -2.60 | -1.76 | -2.55 | -1.88 | -1.28 | -0.69 | -0.76 | -0.65 | -0.35 | -0.75 | -0.78 | -0.63 | -0.34 | -0.24 | 0.03 | 0.15 |
| EPS Diluted | -0.58 | -0.48 | 1.21 | -2.60 | -1.76 | -2.55 | -1.88 | -1.25 | -0.69 | -0.74 | -0.63 | -0.35 | -0.75 | -0.78 | -0.63 | -0.34 | -0.24 | 0.03 | 0.15 |
| Weighted Avg Shares Out | 49.70M | 49.67M | 44.74M | 38.86M | 36.99M | 31.17M | 31.16M | 26.35M | 24.70M | 22.29M | 19.41M | 15.32M | 12.88M | 11.97M | 11.62M | 11.62M | 11.62M | 11.62M | 11.62M |
| Weighted Avg Shares Out (Dil) | 49.70M | 49.67M | 55.61M | 38.86M | 36.99M | 31.17M | 31.17M | 26.85M | 24.70M | 22.98M | 20.01M | 15.32M | 12.88M | 11.97M | 11.62M | 11.62M | 11.62M | 11.62M | 11.62M |
GENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021
Lille, France; Cambridge, MA; January 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today informs its shareholders of certain changes in certain...
GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event
Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that it will be presenting at the following upcoming...
Shareholder Alert: Robbins LLP Announces That Genfit SA (GNFT) is Being Sued for Misleading Shareholders
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $GNFT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) filed a class action complaint against the Company and its officers and directors for alleged...
The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A.
LOS ANGELES--(BUSINESS WIRE)---- $GNFT #classaction--The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A.
BENSALEM, Pa.--(BUSINESS WIRE)---- $GNFT #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $GNFT #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
GENFIT announces the successful completion of a key milestone in the partial buyback and amendment of its OCEANEs
Lille (France), Cambridge (Massachusetts, United States), December 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that it has signed bond repurchase...
GENFIT announces satisfactory preliminary results of its OCEANEs' partial buyback offer
Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that:
GENFIT Announces Final Terms For Proposed Renegotiation of 2022 OCEANE Convertible Bonds
Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the final terms of the partial...
GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience™
Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced that data on NIS4™ technology and...
Source: https://incomestatements.info
Category: Stock Reports